Company intelligence / Profile preview

Nutrivert

Atlanta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

Nutrivert's lead program, Nutrivert LDPP, has shown promising pre-clinical results as a non-antibiotic feed additive for livestock, demonstrating improved growth and feed efficiency in pigs and chickens without the use of antibiotics. Early research also suggests potential for protecting against respiratory viral disease.

Therapeutic areas: Infectious DiseasesEndocrinology
Modalities: PostbioticSmall molecule
Industry: Agriculture & AgTech

Partnerships

Auburn University

Beyond the preview

Go deeper on Nutrivert.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutrivert.

Explore the full profile